UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$234M |
| 2 |
Home Depot
HD
|
+$214M |
| 3 |
Intercontinental Exchange
ICE
|
+$206M |
| 4 |
TJX Companies
TJX
|
+$129M |
| 5 |
BorgWarner
BWA
|
+$122M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$227M |
| 2 |
DFS
Discover Financial Services
DFS
|
+$212M |
| 3 |
Mohawk Industries
MHK
|
+$137M |
| 4 |
Liberty Global Class A
LBTYA
|
+$114M |
| 5 |
Freeport-McMoran
FCX
|
+$112M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.05% |
| 2 | Technology | 13.96% |
| 3 | Financials | 13.95% |
| 4 | Industrials | 9.13% |
| 5 | Energy | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Tandem Diabetes Care
TNDM
$1.38B
| $3.1M | ﹤0.01% |
19,070
-2,150
| -10% | -$366K |
|
|
VRE
1127
DELISTED
Veris Residential
VRE
| $3.09M | ﹤0.01% |
144,035
-128,935
| -47% | -$2.73M |
|
1128
Civeo
CVEO
$338M
| $3.07M | ﹤0.01% |
+10,221
| New | +$3.06M |
|
1129
Visteon
VC
$2.81B
| $3.07M | ﹤0.01% |
31,635
+400
| +1% | +$36.3K |
|
1130
Starwood Property Trust
STWD
$6.03B
| $3.06M | ﹤0.01% |
128,633
+4,000
| +3% | +$95.3K |
|
1131
Graham Holdings Company
GHC
$5.13B
| $3.05M | ﹤0.01% |
7,039
-12,991
| -65% | -$5.41M |
|
|
IMPV
1132
DELISTED
Imperva, Inc.
IMPV
| $3.05M | ﹤0.01% |
116,400
+110,897
| +2,015% | +$2.86M |
|
|
MCRS
1133
DELISTED
MICROS SYSTEMS INC
MCRS
| $3.03M | ﹤0.01% |
44,602
-140,607
| -76% | -$7.69M |
|
1134
Acuity Brands
AYI
$10.4B
| $3.03M | ﹤0.01% |
21,899
+3,700
| +20% | +$470K |
|
1135
Forum Energy Technologies
FET
$836M
| $3.02M | ﹤0.01% |
4,146
+412
| +11% | +$268K |
|
|
AVIV
1136
DELISTED
AVIV REIT INC COM STK (MD)
AVIV
| $3.02M | ﹤0.01% |
+107,100
| New | +$2.9M |
|
|
MPT
1137
Medical Properties Trust
MPT
$2.78B
| $3M | ﹤0.01% |
226,827
+16,900
| +8% | +$224K |
|
|
GWR
1138
DELISTED
Genesee & Wyoming Inc.
GWR
| $2.99M | ﹤0.01% |
28,499
+300
| +1% | +$29.5K |
|
1139
World Kinect Corp
WKC
$2B
| $2.97M | ﹤0.01% |
60,276
+2,100
| +4% | +$96K |
|
1140
Descartes Systems
DSGX
$6.63B
| $2.94M | ﹤0.01% |
205,000
+4,000
| +2% | +$54.3K |
|
1141
Amdocs
DOX
$6.02B
| $2.94M | ﹤0.01% |
63,433
-3,700
| -6% | -$174K |
|
|
P
1142
DELISTED
Pandora Media Inc
P
| $2.94M | ﹤0.01% |
99,478
+21,800
| +28% | +$569K |
|
|
HCC
1143
DELISTED
HCC INSURANCES HOLDINGS INC
HCC
| $2.94M | ﹤0.01% |
59,974
| – | – |
|
|
CIR
1144
DELISTED
CIRCOR International, Inc
CIR
| $2.93M | ﹤0.01% |
38,033
+7,813
| +26% | +$604K |
|
1145
Service Corp International
SCI
$11.7B
| $2.92M | ﹤0.01% |
140,994
+1,700
| +1% | +$33.2K |
|
1146
iShares International Select Dividend ETF
IDV
$8.48B
| $2.92M | ﹤0.01% |
73,065
+25,998
| +55% | +$1.04M |
|
1147
Terex
TEX
$7.55B
| $2.9M | ﹤0.01% |
70,458
+1,400
| +2% | +$56.9K |
|
1148
Jack Henry & Associates
JKHY
$11.1B
| $2.89M | ﹤0.01% |
48,628
-9,907
| -17% | -$565K |
|
1149
Cullen/Frost Bankers
CFR
$10.5B
| $2.85M | ﹤0.01% |
35,883
| – | – |
|
1150
Sonoco
SON
$5.8B
| $2.85M | ﹤0.01% |
64,827
+300
| +0.5% | +$12.7K |
|
Similar funds
UBS AM's Q2 2014 Portfolio in Review
As of Q2 2014, UBS AM held 2,651 positions worth $99B, up 5.7% from $93.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
UBS AM's Q2 2014 filing shows 81 new, 1,135 increased, 556 reduced and 97 closed positions. Its largest new stake was Sabre: 3,529,400 shares worth $70.8M. The largest sale was Allergan Inc, an estimated $227M.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 14% a quarter earlier, followed by Technology and Financials.
- UBS AM's largest Q2 2014 buy was Sabre: 3,529,400 shares worth $70.8M.
- UBS AM added most to Thermo Fisher Scientific in Q2 2014, an estimated $234M increase.
- UBS AM's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $227M.
- UBS AM fully exited Freeport-McMoran in Q2 2014, selling an estimated $112M.
- UBS AM's ten largest holdings make up 14% of its $99B portfolio in Q2 2014.
- UBS AM opened 81 new positions and closed 97 in Q2 2014.
- UBS AM's portfolio value rose 5.7% quarter-over-quarter to $99B.
Based on UBS AM's 13F filing for Q2 2014, filed 13 Aug 2014.